As of November 6, 2026, Rein Therapeutics, Inc. is a publicly traded company (Nasdaq: RNTX); its largest reported holder is Bios Capital Management, LP, with 9.99% on Schedule 13G/A of May 8, 2026, then Funicular Funds, LP (6.7%) (Schedule 13G/A, May 8, 2026).
Is this your company?
About to sign with, pay or invest in Rein Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Rein Therapeutics, Inc. a real, registered company?
- Rein Therapeutics, Inc. files with the SEC under CIK 1420565 (its SEC filings).
- Its shares are listed under the ticker RNTX on Nasdaq (SEC company record).
- business address in Austin, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AILERON THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Lynwood Capital Management Inc. (filed 2026-08-14).
Who are Rein Therapeutics, Inc.'s owners and officers?
Rein Therapeutics, Inc.: business address in Austin, Texas; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-11-16)
- : Executive Officer (Form D, 2023-11-16)
- : Executive Officer (Form D, 2023-11-16)
- : Director (Form D, 2023-11-16)
- : Director (Form D, 2023-11-16)
- : Director (Form D, 2023-11-16)
- : Director (Form D, 2023-11-16)
- : Director (Form D, 2023-11-16)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Lynwood Capital Management Inc. | 5% |
| Schedule 13G, 2026-08-14 | Adar1 Capital Management, LLC | 5.3% |
| Schedule 13G/A, 2026-08-13 | Lytton Laurence W | 4.9% |
| Schedule 13G/A, 2026-07-14 | Voss Capital, LP | 6.6% |
| Schedule 13G/A, 2026-05-08 | Bios Capital Management, LP | 9.99% |
| Schedule 13G, 2026-05-08 | Lynwood Capital Management Inc. | 6.1% |
| Schedule 13G, 2026-05-07 | Funicular Funds, LP | 6.7% |
| Schedule 13G, 2026-05-06 | Lytton Laurence W | 5.8% |
| Schedule 13G/A, 2026-02-13 | Voss Capital, LP | 17% |
| Schedule 13G/A, 2025-09-26 | Voss Capital, LP | 11.3% |
Questions about who owns Rein Therapeutics, Inc.
Who owns Rein Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Rein Therapeutics, Inc.: Bios Capital Management, LP (9.99%, Schedule 13G/A, filed 2026-05-08), Funicular Funds, LP (6.7%, Schedule 13G, filed 2026-05-07), Voss Capital, LP (6.6%, Schedule 13G/A, filed 2026-07-14), Adar1 Capital Management, LLC (5.3%, Schedule 13G, filed 2026-08-14) and Lynwood Capital Management Inc. (5%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Rein Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Rein Therapeutics, Inc. on this page are Bios Capital Management, LP (9.99%), Funicular Funds, LP (6.7%) and Voss Capital, LP (6.6%).
When did Bios Capital Management, LP buy into Rein Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bios Capital Management, LP on this page is the Schedule 13G/A, filed 2026-05-08, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Rein Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Rein Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rein Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Rein Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Voss Advisors GP, LLC, a 10% owner: 1,426,441 shares (1.7% of shares outstanding), held indirectly through By: Voss Value Master Fund, L.P. and 1 other, on a joint filing (Form 4, 2025-11-18).
- Voss Value-Oriented Special Situations Fund, LP, a 10% owner: 1,426,441 shares (1.7% of shares outstanding), held indirectly through By: Voss Value Master Fund, L.P. and 1 other, on a joint filing (Form 4, 2025-11-18).
- Voss Capital, LP, a 10% owner: 1,426,441 shares (1.7% of shares outstanding), held indirectly through By: Voss Value Master Fund, L.P. and 1 other, on a joint filing (Form 4, 2025-11-18).
- , a 10% owner: 1,426,441 shares (1.7% of shares outstanding), held indirectly through By: Voss Value Master Fund, L.P. and 1 other, on a joint filing (Form 4, 2025-11-18).
- Voss Value Master Fund, LP, a 10% owner: 1,426,441 shares (1.7% of shares outstanding), held indirectly through By: Voss Value Master Fund, L.P. and 1 other, on a joint filing (Form 4, 2025-11-18).
Shares outstanding: 86,267,032 as of 2026-08-12, from the company's latest SEC cover page.
How much has Rein Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-11-16 | $18.25M | $18.25M |
Latest IPO step: Rein Therapeutics, Inc. filed to go public (S-1, 2026-04-28).
IPO filings: S-1, 2026-04-28, S-1, 2025-09-03; ticker RNTX on Nasdaq Capital Market.
Keep reading
More on Rein Therapeutics, Inc. and the records around it.
Rein Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Lynwood Capital Management Inc. also filed stake reports on 1 other company: Kazia Therapeutics Limited (Aug 2026)
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Pasithea Therapeutics Corp. (Apr 2026)
- Voss Value Master Fund, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/rein-therapeutics